1-4 of 4
vandetanib
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Concurrent Treatment of VEGFR Tyrosine Kinase Inhibitors (TKIs) and Factor Xa Inhibitors Is Associated with Increased Bleeding Risks

Sandip Patel, MBBS, Tiffany George, MD, Tzu-Fei Wang, MD MPH, Sherry Mori Vogt, Pharm D, Edmund Folefac, MD, Ming Yin, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 3681.
https://doi.org/10.1182/blood-2019-130465
Published: 2019
Journal Articles

The RET Receptor Tyrosine Kinase Promotes Acute Myeloid Leukemia through Protection of FLT3-ITD Mutants from Autophagic Degradation

Saskia Rudat, MSc, Anja Pfaus, MSc, Claudia Bühler, MD, Sophie Rabe, MSc, Lars Bullinger, MD, Stefan Gröschel, MD, Stephen M. Sykes, PhD, Michael D. Milsom, PhD, Jana M. Ellegast, MD, Stefan Fröhling, MD, Claudia Scholl, MD
Journal: Blood
Blood (2016) 128 (22): 2849.
https://doi.org/10.1182/blood.V128.22.2849.2849
Published: 2016
Journal Articles

Development of a Clinically Relevant in Vitro Drug Screening Platform for Chemo-Refractory AML Patients

Stephen Sze Yuen Lam, Chae Yin Cher, Nelson Ka Lam Ng, Eric SK Ho, Cheuk Him Man, PhD, Howard CH Chow, Connie J Eaves, Alice MS Cheung, PhD, Anskar Y.H. Leung, MD
Journal: Blood
Blood (2014) 124 (21): 3624.
https://doi.org/10.1182/blood.V124.21.3624.3624
Published: 2014
Journal Articles

In Vitro Evaluation of the Antitumor Activity of Vandetanib in Pediatric Acute Leukemias.

Margaret E. Macy, MD, Deborah DeRyckere, Ph.D., Lia Gore, M.D.
Journal: Blood
Blood (2007) 110 (11): 857.
https://doi.org/10.1182/blood.V110.11.857.857
Published: 2007